Rethink Your Non-Interventional Research at SCOPE Summit 2026

Current clinical research models—marked by slow activation, unpredictable enrollment, and costly patient drop-off—still rely on patient engagement strategies that have not fundamentally changed despite technology advances. But what if the biggest gains came from redesigning studies around patients from day one? This roundtable explores how patient-first models, powered by emerging AI capabilities, are unlocking faster and more scalable, efficient studies—and what this shift means for sponsors evaluating the next generation of clinical research tools.

The goal of this session is to Activate the Call to Action for enabling a Proposed Proof Concept: a sponsor-agnostic human + digital trial navigator and meaningful data sharing at scale. We will explore trust and reciprocity through proactive compliant Data Sharing by Design, evidence-driven informed stakeholder decision-making and equity/techquity in access, and secure stakeholder understanding and commitments. Why now? What does the data suggest? How can digital and AI accelerate equity in access? How can we persuade all stakeholders to agree on the need for a cultural process and operational shift that truly impacts patients?

Long-term follow-up (LTFU) is central to safety and pharmacovigilance. Yet 15 years of visits are unsustainable for patients, resulting in attrition that weakens signal detection, jeopardizes regulatory commitments, and leaves long-term benefit–risk unanswered.

This discussion between a clinical researcher and patient advocate reimagines long-term follow-up studies through a “retention by design” lens. The conversation will center around designing LTFU studies from the outset around pharmacovigilance objectives and patients’ lives.